13 - 15 November, 2018 | Hilton London Kensington, London, United Kingdom

Conference Day 1

8:30 am - 8:55 am Registration and Welcome Coffee

8:55 am - 9:00 am PharmaIQ Welcome

9:00 am - 9:10 am Chairman's Opening Address

9:00 am - 9:40 am Opening Keynote: Manufacturing Cell and Gene Therapy Products: Looking at the Potential and the Reality

Professor Brendon Noble - CSO & Director of Strategy UK Stem Cell Foundation, The Royal Institution of Great Britain
  • Analyse the industry development trends of the past 6-12months; where the industry is now and what are the biggest barriers to further development?
  • Discuss the importance of ‘Flexible’ and ‘Scalable’ Manufacturing processes – why do you need to worry about this now?
  • Move to Market – Identify industry developments in cost efficiency of manufacturing
img

Professor Brendon Noble

CSO & Director of Strategy
UK Stem Cell Foundation, The Royal Institution of Great Britain

  • Discuss the realities of Cell and Gene Development, and the challenges our industry is currently facing, with valuable insights and feedback from our industry experts. Discussions will cover the realities of commercialising novel therapies without an established model, the challenges of scaling product development when working with such fragile and changeable materials and the difficulty in anticipating industry development and demand without established case studies as a basis.
img

Robert Allen

Senior Director, Immunotherapy Programme
Asterias Biotherapeutics

img

Mark Woodyer

Technical Lead, Manufacturing Sciences & Technology
Oxford Biomedica

img

Fatma Senkesen

Head of Market Insights - Cell & Gene Therapy
Lonza

img

Omar Ali

Visiting Lecturer Value Based Pricing and Former Advisor
University of Portsmouth and NICE

10:20 am - 11:00 am Industrial Purification Platform of Adeno Associated Virus

Ales Strancar - Managing Director BIA Separations
  • Discuss why adeno associated virus (AAV) is the leading vector of choice in the field of gene therapy.
  • Analyse the effects of shear and concentration methods in promoting stable associations between virus’, DNA and proteins
  • Examine the benefit of monolithic purification in increasing the speed of product capture, flow rates and column loading
  • Highlight an exclusively monolithic purification platform that includes three chromatographic steps and is fully scalable and effective for all AAV serotypes evaluated to date
img

Ales Strancar

Managing Director
BIA Separations

11:00 am - 11:30 am Morning Coffee Break

11:30 am - 12:10 pm Can we Afford a Cure? Payers Perspective on Drug Leasing & Innovative Reimbursement for Curative Medicines

Omar Ali - Visiting Lecturer Value Based Pricing and Former Advisor University of Portsmouth and NICE
  • Analyse a fiscal overview of global healthcare payer landscape & medicines
  • Discuss the difficulty of valuing innovation from a reimbursement perspective
  • Utilise real world data to secure payer approval in conditional reimbursement models and the cancer drugs fund
  • Examine the ground breaking drug leasing concept for CAR-T curative therapies – with reference to the original publication with Guy’s & St.Thomas Hospital
img

Omar Ali

Visiting Lecturer Value Based Pricing and Former Advisor
University of Portsmouth and NICE

  • Discuss the current European and US regulatory landscape, and the key differences for manufacturers to be aware of.
  • Harmonisation – fact or fiction? Look at the European requirements post 2008, assessing where they fall short of industry requirements and demand
  • Plan for the future by predicting further guidelines to emerge and how this will challenge ‘being GMP compliant’
  • The Brexit effect! Discuss how the political landscape and changes such as Brexit will alter the GMP requirements
img

David Sourdive

Executive Vice President Technical Operations
Cellectis

img

Robert Piperno

Director Cell and Gene Therapy QA
GSK

img

Bryan Deane

Head of Production and Process Innovation
ABPI

12:45 pm - 1:45 pm Networking Lunch

1:45 pm - 2:25 pm Interactive Round Tables

Choose from 3 different round table discussions to participate in and exchange industry best practice to drive your development forward

Round Table 1: Open and Closed System Processing – Same problem, new solutions!

Round Table 2: Identifying a Risk Based Strategy for Commercialising Cell and Gene Therapy Products

Round Table 3: Defining the Critical Quality Attributes for your Products

Round Table 4: Analysing the Global Regulatory Landscape you Need to Navigate on the Route to Market

2:25 pm - 3:05 pm Case Study: The Balancing Act: Quality Assurance and Scalability for Efficient CAR T Production

William Newell - Process Development Engineer ReNeuron
  • Define the Critical Success Factors for stem cell production viability
  • Reduce the risk of shortfall by proactively managing your production strategy to allow for the move towards off-the shelf models
  • Future proof your development by discussing the application of QbD metrics as a means of defining your development pathway
img

William Newell

Process Development Engineer
ReNeuron

  • Discuss the importance of a good strategy to develop a viral vector process
  • Evaluate the impact of GMP requirements on viral vector development
  • Analyse the effect of access to multiple plans to supply GMP vector
img

Eugenio Macchiarulo

Vector Development Associate Director
Adaptimmune Ltd

3:45 pm - 4:15 pm Afternoon Coffee Break

4:15 pm - 4:55 pm Case Study: Ensuring Viable and Precise Production of Autologous TCR-T Cells

Arjan Roozen - CTO and Head of Manufacturing Zelluna Immunotherapy
  • Discuss the challenges of scaling Autologous Cell Production with reference to viability and precision of treatment
  • Analyse specialised manufacturing techniques to enhance natural production
  • Cost vs Gain: looking at the reality of implementing new technology when demand is hard to forecast
img

Arjan Roozen

CTO and Head of Manufacturing
Zelluna Immunotherapy

4:55 pm - 5:35 pm Implementing Process Change and Comparability for Autologous Product Production

Nina Kotsopoulou - Head, Process Development Autolus
  • Analyse the unique challenges presented by the CGT space with specific reference to CAR T Therapies
  • Avoid the common manufacturing pain-points by identifying your manufacturing bottlenecks
  • Prevent costly back-tracking by implementing a flexible process design to cope with unexpected situations
img

Nina Kotsopoulou

Head, Process Development
Autolus

5:35 pm - 5:45 pm Chairman's Summary of Day One